[EN] NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS<br/>[FR] NOUVEAUX DÉRIVÉS D'ADAMANTYLE EN TANT QU'AGONISTES DU RÉCEPTEUR 2 DE CANNABINOÏDES
申请人:HOFFMANN LA ROCHE
公开号:WO2014005968A1
公开(公告)日:2014-01-09
The invention relates to a compound of formula (I), wherein i.a. A1is -CH2- or -C(O)-; one of R1 and R2 is hydrogen and the other one is -A2 -C(O)-R3; A2 is NH- or absent; and R3 is (A), (B) or (C) The compounds are preferential agonists of the cannabinoid receptor 2 (CB2) and can be used as medicaments for the treatment of pain, inflammation, ischemia, etc.
Adamantyl derivatives as cannabinoid receptor 2 agonists
申请人:Hoffmann-La Roche Inc.
公开号:US09090615B2
公开(公告)日:2015-07-28
The invention relates to a compound of formula (I)
wherein A1, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS
申请人:Hoffmann-La Roche Inc.
公开号:US20150111886A1
公开(公告)日:2015-04-23
The invention relates to a compound of formula (I)
wherein A
1
, R
1
and R
2
are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.